ALX-0141: Additional Phase I data

Additional data from a double-blind, placebo-controlled Phase I trial in 42 healthy postmenopausal women showed that 4 of 6 subjects receiving a single subcutaneous injection of 1 mg/kg ALX-0141 had s...